WebAug 17, 2024 · Abstract Oxidative stress, inflammation, and apoptosis are crucial in the pathogenesis of acute liver failure (ALF). 4-Octyl itaconate (OI) showed antioxidative and anti-inflammatory properties in many disease models. However, its role in lipopolysaccharide- (LPS-)/D-galactosamine- (D-GalN-) induced ALF is still not investigated. WebDec 1, 2024 · The current study innovatively used 4-octyl itaconate (OI), a cell-permeable derivative of an endogenous anti-inflammatory metabolite itaconate (IA), to regulate the polarization of macrophages and enhance the quality of bone repair. Chitosan (CS) was selected as a bridge in coating OI on demineralized bone matrix (DBM) scaffold to …

Itaconate: the poster child of metabolic reprogramming in ... - Nature

Web4-Octyl itaconate [CAT#: NCM-2102-FP1801] Biological Activity: Activates Nrf2. Inhibits LPS-induced increases in IL-1β mRNA, HIF-1α and IL-10 in macrophages. Decreases cytokine production in response to LPS in mice and prolongs survival. Cell permeable. Datasheet MSDS Request COA. WebNov 15, 2024 · The expression of IRG1 is predominantly restricted to macrophages and several other immune cell types and is markedly upregulated on stimulation with TLR ligands , thereby leading to an increase in intracellular itaconate. 4-Octyl itaconate (4-OI) is a cell-permeable derivative that is commonly used in the study of itaconate and has … fear of intimacy books

Four-Octyl Itaconate Attenuates UVB-Induced Melanocytes and ... - Hindawi

WebDec 1, 2024 · Four-octyl itaconate (4-OI) is a cell-permeable itaconate derivative and has been recognized as a promising therapeutic target for the treatment of inflammatory diseases. WebSep 17, 2024 · Four-octyl itaconate (4-OI) is the cell-permeable derivative of itaconate that can activate Nrf2 signaling by alkylating Keap1’s cysteine residues. Here, we tested the potential effect of 4-OI on hydrogen peroxide (H2O2)-induced oxidative injury in osteoblasts. WebApr 15, 2024 · The effects of 4-octyl itaconate (4-OI) on DSS-induced colitis in acod1 −/− mice. (A) The experimental scheme for the administration of DSS and 4-OI. The 4-OI agent was injected intraperitoneally daily at 25 mg/kg for 7 days. (B) The administration of 4-OI reduced the body weight loss caused by DSS-induced colitis in acod1 −/− mice. debian access denied for user root localhost